AAV-mediated gene therapy
/ DegenRx
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 02, 2020
[VIRTUAL] AAV mediated gene therapy as local treatment modality directed against amyloid beta oligomers in the brain using a high affinity, high specificity antibody
(AAIC 2020)
- "Recombinant AAV-5 vector encoding for the antibody is tested positive in vitro and in vivo, suggesting that the antibody can be expressed and secreted in the brain to target AB oligomers at the site where it is needed. Future studies should reveal whether native AB oligomers are also recognized and efficiently neutralized in an appropriate mouse model of AD resulting in enhanced cognitive performance."
IO Biomarker • Alzheimer's Disease • CNS Disorders
August 02, 2020
[VIRTUAL] AAV mediated gene therapy as local treatment modality directed against amyloid beta oligomers in the brain using a high affinity, high specificity antibody
(AAIC 2020)
- "Recombinant AAV-5 vector encoding for the antibody is tested positive in vitro and in vivo, suggesting that the antibody can be expressed and secreted in the brain to target AB oligomers at the site where it is needed. Future studies should reveal whether native AB oligomers are also recognized and efficiently neutralized in an appropriate mouse model of AD resulting in enhanced cognitive performance."
IO Biomarker • Alzheimer's Disease • CNS Disorders
1 to 2
Of
2
Go to page
1